TOLREMO therapeutics’ Post

Back in 2021, TIGITs were hot with over $10B in deals signed and five assets racing to market. Today, the landscape has shifted, with recent news about two TIGITs - one good and one bad. Read on to learn more about the past and future of this class. #oncology #TIGITs #cancer #biotech #pharma

Fragmentomics is a wonderful concept in liquid biopsy. Similar to a muti-omics solution, fragmentomics looks at the composition of cf-DNA (length profile traditionally) to identify the ct-DNA profile. From here you can infer all sorts of useful information about the patients cancer. What makes it different from multi-omics is that you use the same DNA assay as for standard liquid biopsy. So twice the bang for a single buck! Seems like most ct-detection projects will soon be adding this to their arsenal. Up next, how to merge fragmentomics analysis with traditional variant calling? Im sure somebody's done it already...!

Unraveling the Complexities of Cancer. Join me for our upcoming webinar, where we will discuss developing new predictive and robust PDX based drug development platforms Register here for the webinar on June 25, 2024. URL - https://bit.ly/3Kpwz7c

CAR-T therapy is rewriting the rules in the fight against cancer and beyond. Imagine taking your cells, supercharging them to hunt down cancer, and unleashing them back into your body—a reality in 2024. UCLA's breakthrough against melanoma, Penn Medicine's safety affirmations, and the FDA's guiding light mark milestones in this journey. It's not just treatment; it's a revolution in healing, promising a future where cancer's threat dims. Dive into the science shaping tomorrow, where every advancement is a step closer to victory. Opal Bio Pharma (OBP) #CAR-T #CancerFighter #InnovationInHealing #ScienceForFuture

Unraveling the Complexities of Cancer. Join me for our upcoming webinar, where we will discuss developing new predictive and robust PDX based drug development platforms Register here for the webinar on June 25, 2024.  URL - https://bit.ly/3Kpwz7c

Unraveling the Complexities of Cancer. Join me for our upcoming webinar, where we will discuss developing new predictive and robust PDX based drug development platforms Register here for the webinar on June 25, 2024. URL - https://bit.ly/3Kpwz7c

This is an interesting perspective on the TIGIT landscape. I'm curious to learn more about this recent news and how it will impact the future of this class of drugs.

As #oncology continues to drive growth in the global pharma market, there is increasing interest in new combinations and drug modalities. Explore the trends and innovation shaping the future of #cancer care in this new blog. https://bit.ly/3UQngTJ #IQVIAMIDAS #AnalyticsLink

In this exclusive interview, we have a special guest, Dr. Reggie Ewesuedo, Vice President of Clinical Development at Lantern Pharma Inc. (Nasdaq: LTRN), to discuss 'Breakthrough in #LungCancer Treatment for Never Smokers' including the novel #AI-assisted drug candidate #LP300. We'll dive into the promising results of the #HARMONIC Phase 2 trial, focusing on LP-300 and its significant implications for treating #lung #cancer. Additionally, we’ll explore the transformative role of #artificialintelligence in #drugdiscovery, particularly how it's reshaping #clinicaltrials and treatment strategies. https://lnkd.in/dVbpWEmm

Join your peers for this must-attend #webinar reviewing different types of linkers and payloads used in antibody-drug conjugates, as well as key methodologies involved in developing robust bioassays for #ADCs. Register today to gain access to the live event and on-demand recording. #medicinalchemistry #biotechnology #ADC #cellbasedassay #drugdiscovery #biology #chemistry #CDMO